These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 4468748)

  • 41. [The production of neutralizing antibodies in man after vaccination with Hempt-rabies-vaccine (author's transl)].
    Schoop G; Schoop HD; Berger J; Wachendörfer G; Helm B
    Zentralbl Bakteriol Orig A; 1974; 229(3):279-89. PubMed ID: 4155877
    [No Abstract]   [Full Text] [Related]  

  • 42. [Characteristics of a low-molecular nonvirion ("soluble") antigen from the tick-borne encephalitis virus].
    Liapustin VN; Zhankov AI; Dzhivanian TI; Lashkevich VA
    Vopr Virusol; 1983; (2):200-7. PubMed ID: 6868559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rabies virus strains: a comparison study by polypeptide analysis of vaccine strains with different pathogenic patterns.
    Dietzschold B; Cox JH; Schneider LG
    Virology; 1979 Oct; 98(1):63-75. PubMed ID: 483574
    [No Abstract]   [Full Text] [Related]  

  • 44. In vitro potency tests: challenges encountered during method development.
    Yomayuza CL; Thiel HJ; König M
    Dev Biol (Basel); 2012; 134():93-100. PubMed ID: 22888600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Preparation of an immunizing glycoprotein from inactivated rabies vaccine (author's transl)].
    Atanasiu P; Tsiang H
    Comp Immunol Microbiol Infect Dis; 1979; 1(3):179-84. PubMed ID: 519971
    [No Abstract]   [Full Text] [Related]  

  • 46. [Passive immunization against rabies (author's transl)].
    Kuwert EK
    Immun Infekt; 1978 Apr; 6(2):53-61. PubMed ID: 649182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Studies on Epstein Barr virus (EBV)-related antigens: biochemical characterization and purification of EBV-determined nuclear antigen (EBNA) (author's transl)].
    Matsuo T
    Hokkaido Igaku Zasshi; 1979 Jan; 54(1):49-60. PubMed ID: 223952
    [No Abstract]   [Full Text] [Related]  

  • 48. A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice.
    Koraka P; Bosch BJ; Cox M; Chubet R; Amerongen Gv; Lövgren-Bengtsson K; Martina BE; Roose J; Rottier PJ; Osterhaus AD
    Vaccine; 2014 Aug; 32(36):4644-50. PubMed ID: 24962755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Potency testing of inactivated rabies vaccines with the antibody binding test in comparison with the NIH and habel test(author's transl)].
    Oei HL; Krauss H
    Zentralbl Bakteriol Orig A; 1975; 231(1-3):1-14. PubMed ID: 1154901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New vaccines for immunization of man: new approaches towards the prevention of rabies in man.
    Sureau P
    Parassitologia; 1988; 30(1):141-8. PubMed ID: 2478948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Current status of the rabies problem].
    Pille ER; Vagabov RM
    Usp Sovrem Biol; 1981; 92(1):140-52. PubMed ID: 7027662
    [No Abstract]   [Full Text] [Related]  

  • 52. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice.
    Li J; Faber M; Papaneri A; Faber ML; McGettigan JP; Schnell MJ; Dietzschold B
    Virology; 2006 Dec 5-20; 356(1-2):147-54. PubMed ID: 16938327
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progress towards rabies control.
    Ferguson M
    Trends Biotechnol; 1991 Jan; 9(1):7-11. PubMed ID: 1366926
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Experimental study of an antirabies vaccine from sheep brain tissue inactivated by UV rays (author's transl)].
    Pospeeva NA; Morogova VM; Gil'dina SS; Nikolaeva NV; Losev MN
    Vopr Virusol; 1975; (5):578-81. PubMed ID: 1210319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rabies virus-like particles expressed in HEK293 cells.
    Fontana D; Kratje R; Etcheverrigaray M; Prieto C
    Vaccine; 2014 May; 32(24):2799-804. PubMed ID: 24631077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rabies virus.
    Matsumoto S
    Adv Virus Res; 1970; 16():257-301. PubMed ID: 4100061
    [No Abstract]   [Full Text] [Related]  

  • 57. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein.
    Fujii H; Takita-Sonoda Y; Mifune K; Hirai K; Nishizono A; Mannen K
    J Gen Virol; 1994 Jun; 75 ( Pt 6)():1339-44. PubMed ID: 8207400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Rabies (author's transl)].
    Beer K
    Schweiz Rundsch Med Prax; 1979 Oct; 68(43):1416-7. PubMed ID: 230472
    [No Abstract]   [Full Text] [Related]  

  • 59. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals.
    Lodmell DL; Esposito JJ; Ewalt LC
    Vaccine; 2004 Sep; 22(25-26):3329-33. PubMed ID: 15308356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A rabies virus persistent infection in BHK21 cells.
    Wild TF; Bijlenga G
    J Gen Virol; 1981 Nov; 57(Pt 1):169-77. PubMed ID: 7320704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.